China has introduced new regulations requiring manufacturers of traditional Chinese medicine injections to provide scientific evidence of efficacy and safety. Companies that cannot meet these evidence standards must withdraw their products from the market.
The regulatory shift represents a significant departure from traditional approval processes for Chinese medicine products, which historically relied less on rigorous clinical testing. The move reflects growing emphasis on evidence-based medicine within China's healthcare system.